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PRACTICE VARIATION IN SUPPORTIVE CARE IN HEMATOPOIETIC CELL
TRANSPLANTATION
Lee, S.J.1, Eapen, M.1, Soiffer, R.J.1, McCarthy, P.L.1, Loberiza, F.1,
Kernan, N.A.1, Jagasia, M.1, Davies, S.1, Artz, A.1, Joffe, S.1 1Center
for International Blood and Marrow Transplant Research, Milwaukee,
WI.
Background: No studies describe individual physician practices
in hematopoietic stem cell transplantation (HCT). We conducted
an international Internet-based survey of physicians to explore the
spectrum of supportive care practices in HCT. Methods: Ques-
tions addressed pre-HCT patient and donor testing, infectious
disease prophylaxis and treatment, and protective isolation recom-
mendations after HCT. Response options were closed-ended of-
fering several management approaches. The response rate was
526/627 (84%) of eligible physicians who conﬁrmed receipt of the
invitation, or 526/1823 (29%) of all invitations. Respondents were
clinically active with a median of 2.5 days in clinic and 4 months
inpatient service (60% clinical effort). 57% practiced in the U.S.
Results: Measurement of cardiac and pulmonary function and
requirement for signed informed consent before HCT was almost
universal (90%). Though use of antifungal prophylaxis was rou-
tine (90-96%), other measures such as myeloid growth factors
(45-79%), antibacterial prophylaxis (50-79%) and ursodeoxycholic
acid (22-41%) were less common. Approximately half used a single
agent broad spectrum antibiotic for empiric treatment of febrile
neutropenia, while a third used combination therapy that included
an aminoglycoside. While 94-97% recommended handwashing
and 73-86% used hepa-ﬁltration,  50% used other isolation
procedures during hospitalization (e.g., masks, gloves, gowns).
Recommendations for protective isolation after HCT, such as
visitors in the home, use of masks and/or gloves in public, eating
out, going to indoor public places (median  100 days) and return
to work/school (median 3-6 months) were variable, but stricter
policies were predicted by allogeneic/myeloablative and pediatric
versus adult practice. Other physician characteristics, such as US
vs. non-US and shorter time since completion of fellowship also
predicted stricter isolation recommendations and appear less bio-
logically justiﬁable. Conclusions: Our results demonstrate the
heterogeneity of supportive care practices in HCT. For most
practices, little data exist to favor one approach over another.
Where data do exist, as for antifungal prophylaxis and ursodeoxy-
cholic acid during myeloablative procedures, uptake into standard
practice is variable. Although the relative contribution of support-
ive care management to overall success of HCT is unknown, the
diversity of supportive care approaches suggests randomized stud-
ies are possible.
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PREVALENCE OF FALLS AND SUBSEQUENT PATTERNS OF INJURY IN A
PEDIATRIC ONCOLOGY HOSPITAL
Mattox, S.1, Dycus, P.1, Hale, G.A.1 1St. Jude Children’s Research
Hospital, Memphis, TN.
Falls are a signiﬁcant cause of morbidity in hospitalized patients,
but are primarily documented in older adults. Little data is pub-
lished regarding falls in children and adolescents. Pediatric patients
are at risk for falling because of neurologic disease, medication-
related causes, post-operative sequelae, and as part of normal
childhood development. We now report the experience with inpa-
tient and outpatient falls at a pediatric tertiary care facility for
patients with catastrophic diseases. Data was collected through the
hospital incident reporting system from 4/1/2000, to 2/28/2006.
Observation was done by the employee who witnessed the event.
193 patients fell 231 times during this time period: 43 in outpatient
areas and 150 while hospitalized. The median age was 7 years
(range, 6 months to 23 years) and 111 were male. Trauma to the
head or facial area occurred in 41% of the patients. Areas that most
outpatient falls occurred were clinic exam rooms (16), hallways
(15), waiting areas (8) and the Rehabilitation Department (6).
Three occurrences happened while patients were being weighed on
scales. Sixty-four inpatient falls occurred in patient’s room. Ap-
proximately 33% of the inpatient falls were either in the patient’s
bathroom or related to the patient ambulating to or from the
bathroom. Diagnoses of patients included, 79 leukemia/lymphoma,
65 solid tumor, 38 brain tumor and 11 non-malignant patients. 14
patients had undergone autologous HSCT and 27 allogeneic
HSCT (9 MSD, 7 MUD, 11 MMFM). The total number of falls
was 54. Of the HSCT patients who fell, they were a median of 93
days post-HSCT; 16 had acute or chronic GVHD. Pediatric falls
occur commonly in all areas of the hospital, but are more common
on inpatient units. Institutional measures to prospectively identify
pediatric patients at risk for falling are needed in order to initiate
falls prevention programs in children’s hospitals.
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THE SIGNIFICANCE OF PALIFERMIN (KEPIVANCE) IN REDUCTION OF
ORAL MUCOSITIS (OM) INCIDENCE AND ACUTE GRAFT VERSUS HOST
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Oral mucositis is a frequent complication of myeloablative
therapy and HSCT with no effective treatment. We tested the
ability of palifermin (rHuKGF) to reduce the incidence, dura-
tion, and severity of OM induced by high-dose chemotherapy
followed by HSCT in patients (pts) with hematologic malignan-
cies and evaluated the need for analgesics and parenteral nutri-
tion administered because of OM, incidence of febrile neutro-
penia (38°C), and severe infections. Palifermin inﬂuence on
hematopoietic recovery, acute graft vs host disease (aGvHD),
and duration of hospitalization after HSCT were also assessed.
106 pts with hematologic malignancies were enrolled; 53 (50%)
received palifermin (60 mcg/kg/d) for 3 consecutive days before
and after conditioning therapy. Median ages of the palifermin
and historical control groups were 37 yrs (range, 19–58) and
36.1 yrs (range, 18–64), respectively. 30 (5%) autologous and 23
(43%) allogeneic HSCT were done in the palifermin group and
28 (53%) and 25 (47%) in the control group. OM was graded
daily after autoHSCT according to the WHO scale. Incidence
of grade 1-4 OM was 58% for palifermin and 94% for control.
Grade 3-4 incidence was 13% for palifermin and 43% for
control (p0.001). Among all pts, median duration of OM was
4 d (range, 0–16) for palifermin and 9 d (range, 0–28) for
control (p0.001). Compared with control, palifermin was as-
sociated with signiﬁcant reductions in use of analgesics (32% vs
76%), opioid analgesics (24% vs 64%), and parenteral nutrition
(11% vs 45%) (p0.001). aGvHD incidence was reduced for the
palifermin group (25% vs 50%; p0.03), especially the gastro-
intestinal form (8% vs 29%; p0.03 ). No signiﬁcant differences
in febrile neutropenia and severe infections incidences were
observed. Palifermin did not impair reconstitution of the hema-
topoietic system (Table) and did not signiﬁcantly reduce the
median duration of hospitalization (24.5 d, range 10–60 for
palifermin vs 28 d, range 10–83 for control). The drug was
generally well tolerated. Adverse events included rash, pruritus,
erythema, generalized edema, mouth/tongue thickness and dis-
coloration, taste alteration, and proteinuria. Palifermin signiﬁ-
cantly reduced the incidence, severity, and duration of OM
without a negative effect on engraftment in pts with hemato-
logic malignancies after HSCT. The incidence of aGvHD also
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seemed reduced, especially the gastrointestinal form. Palifermin
was generally well tolerated and safe.
ANC>0.5109/l PLT>20109/l
Palifermin group
median (d) 16.7 16.6
range 9-42 8-45
Control group
median (d) 16.7 17.6
range 8-34 7-54
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ADENOVIRUS (ADV) INFECTIONS FOLLOWING ALLOGENEIC STEM
CELL TRANSPLANT (ALLOSCT) IN CHILDREN AND ADOLESCENT RECE-
PIENTS
Oesterheld, J.1, George, D.1, Bradley, B.1, Del Toro, G.1, Garvin, J.1,
Bhatia, M.1, Satwani, P.1, Roman, E.1, Cooney, E.1, Militano, O.1,
Hawkes, R.1, Wowolnik, K.1, Foley, S.1, Schwartz, J.3, Cairo, M.S.1,2,3
1Departments of Pediatrics; 2Medicine and; 3Pathology, New York-
Presbyterian, Columbia University, New York, NY.
ADV is a serious cause of morbidity and mortality in patients
undergoing alloSCT. ADV infection rates are 4-6% in adults
and as high as 47% in children following alloSCT (Hoffman et
al BBMT 2001). The reported mortality rate for disseminated
ADV ranges from 8-54 % with higher rates reported in patients
with ADV pneumonia (73%) and disseminated disease (61%)
(Ljungman, Eur J Clin Microbiol & Infect Dis, 2004). We
sought to determine the incidence, demographics, site of dis-
ease, treatment course, and outcome of ADV infection in chil-
dren and adolescents following alloSCT from 1/1/2000-12/31/
04. Eighty three children and adolescents underwent 91
alloSCT. Median age 6.5 (0.5 – 21.75) years, sex: M/F (52/39).
AlloSCT donors included: Matched Family Donor (MFD),
Bone Marrow (BM)/Peripheral Blood (PB) – 34 (37.4%), Un-
related Cord Blood(UCB) – 51 (56%), Related Cord Blood-
(RCB) - 3 (3.3%), Matched Unrelated Donor(MUD) – 3 (3.3%).
Conditioning: 36 (40%) ablative conditioning, 55 (60%) re-
duced intensity conditioning. The majority (90%) received
Mycophenolate Mofetil/Tacrolimus GVHD prophylaxis (Os-
unkwo/Cairo et al, BBMT 2004). Recipients at risk for CMV
received Foscarnet/Ganciclovir prophylaxis (Shereck/Cairo et al
PBC 2006). ADV swabs and tissue biopsies samples cultured in
remel microtest viral media. Ten (11%) systemic and/or inva-
sive ADV infections were identiﬁed. Underlying diagnosis: 5
malignant (1ALL, 1 AML, 1 NHL, 2 NBL), 5 non-malignant
(1WAS, 4 SAA). Donor source: 4 UCB, 1 MUD, 2 MFDPB, 1
MFDBM, 2 MFDBM  PB. Sites of ADV  culture: Gastro-
enteritis (GE) – 4, GE/Pneumonitis – 3, GE/Nasopharyngeal –
2, Cystits – 1. Treatment (Tx): cidofovir (CDV) (1mg/kg TIW)
[n8], observation [n1], ADV found on post-mortem culture
[n1]. Outcome: 8 expired (6 non-ADV infection, 1 GVHD, 1
CNS hemorrhage); 2 survivors (1 post tx with no evidence of
ADV, 1 ADV  no tx.) There were no ADV related deaths for
0% mortality. Adenovirus infection is an important contributor
to post alloSCT morbidity and mortality. In patients trans-
planted at our center from 1/2000 –12/31/04 there was an 11 %
incidence of adenovirus infection. Tx with CDV improves the
outcome of patients with ADV infection in the post-transplant
period. More rapid diagnosis with PCR-based technology will
allow earlier diagnosis of systemic disease in alloSCT recipients
resulting in prompt therapeutic intervention which may lead to
improved outcomes.
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THROMBOTIC COMPLICATIONS: ETIOLOGY, TREATMENT AND OUT-
COME POST-AUTOLOGOUS AND ALLOGENEIC HEMATOPOEITIC STEM
CELL TRANSPLANT. A SINGLE CENTER EXPERIENCE
Peres, E.M.1, Abidi, M.2, Ibrahim, R.3, Mellon-Reppen, S.4 1Karmanos
Cancer Institute, Detroit, MI.
Introduction: Thrombotic complications are not uncommon
pre or post hematopoietic stem cell transplant (HSCT). However,
little is known about the etiology, frequency of inherited disorders
associated with thrombosis (factor V Leiden, Prothrombin variant
or MTHFR polymorphisms) treatment and outcome of these pa-
tients with thrombotic events during autologous or allogeneic
HSCT. METHODS: We have retrospectively evaluated 65
HSCT patients (n 42 autologus and n 13 allogeneic), for the
presence of thrombotic complications from the start of condition-
ing therapy until 100 days post HSCT from July 1998 to July 2006.
A total of 65 patients presented with a thrombotic event during the
investigational period. Most thrombotic episodes occurred within
the ﬁrst 4 weeks of admission. All patients were evaluated with
either venous Doppler or echocardiographic testing prior to initi-
ation of therapy. All patients were treated with low-molecular-
weight-heparin according to a in-house protocol as previous pub-
lished (Bone Marrow transplantation 2005: 35(11):1071-7.)
Molecular assays were performed for the following hypercoaguable
conditions: MTHFR C677T, homocysteine levels, Factor V-lei-
den deﬁciency, AT-III, Protein C & S and sticky platelet syn-
drome. Results For the entire group 97% of the cohort had a
molecular defect: 47% were MTHFR C677T either homozygous
or heterozygous gene polymorphisms, Factor V leiden 13% and
hyperhomocysteine in 47% (mean homocysteine level 15.5 ) and
53% had sticky platelet syndrome. Conclusion: Our data suggest
that HSCT patients who develop a thrombotic event during the
ﬁrst 100 days of transplantation should be evaluated for, hyperco-
aguable states by conventional methods using molecular anaylsis.
Also, this group of patients is at high risk for the complications of
DVT and should be treated with conventional anticoagulation
when feasible.
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CARDIAC COMPLICATIONS IN PATIENTS UNDERGOING A REDUCED
INTENSITY CONDITIONING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT): A SINGLE CENTER EXPERIENCE
Abidi, M.H.1, Ibrahim, R.2, Mellon-Reppen, S.3, Peres, E.1 1Karmanos
Cancer Institute, Detroit, MI.
Background: RIC regimens can be used to extend transplanta-
tion to elderly or debilitated patients, not normally considered for
stem cell transplants (SCT). Cardiac complications have been re-
ported in patients undergoing fully myleoablative HSCT. How-
ever, in patients undergoing RIC the incidence, predisposing risk
factors, and outcome in patients who develop cardiac complica-
tions is unknown. METHODS: We retrospectively reviewed the
outcome of patients who suffered a cardiac complication during the
time period from July 2000 until July 2006. During that time
period 97 HSCT encompassed a RIC regimen. A total of 13
patients during the investigational period sustained a cardiac event.
Most events occurred within the pre and peri-transplant period. All
patients were evaluated by laboratory evaluation, cardiology and
echocardiographic testing. Results: All patients underwent condi-
tioning with Busulfan 3mg/kg, ﬂudarabine 25mg/m2 and TBI
followed by allogeneic HSCT from a related HLA-matched donor
(n4) or a matched unrelated donor (n9) stem cell source was
peripheral blood (n13). GVHD prophylaxis was tacrolimus and
mycophenolate (MMF) (n13). Median age was 55 years (range
42-66), median day onset was 3 (range day -3 to 9), arrhythmias:
Atrial ﬁbrillation (n7), Atrial ﬂutter (n5) Supraventricular
tachycardia (n1). Troponin was elevated in 6/13 (46%) of pa-
tients, median BNP was 679 (range 488-989), electrolyte abnor-
malities occurred in (n8/13) patients. Hemodynamic compro-
mise occurred in 7/13 (53%) of patients, 5/13 (38%) required
intubation and mechanical ventilation. Median time to medical
conversion was 2 days no mechanical cardio version was required.
Relapse occurred in 4/13 (30%) of patients after discharge. Pre-
disposing risk factors for cardiac complications in our group con-
sisted of 4/13 having a pre-existing cardiac condition, 69% (9/13)
had received anthracycline based therapy in the past. Conclusion:
The incidence of a cardiac complication in the study group at our
center was 13% (13/97), a prior history of a cardiac event or
exposure to anthracycline based therapy was a signiﬁcant risk factor
Poster Session I78
